EVO301 treatment for moderate to severe atopic dermatitis
A Randomized, Double-blind, Placebo-controlled, Proof-of-concept Study of EVO301 in Adults with Atopic Dermatitis
This study is testing if an intravenous treatment called EVO301 can help adults with moderate to severe atopic dermatitis feel better and improve their skin condition.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Evommune, Inc. Industry-sponsored |
| Locations | 12 sites (Coorparoo and 11 other locations) |
| Trial ID | NCT06723405 on ClinicalTrials.gov |
What this trial studies
This Phase 2a study evaluates the efficacy and safety of intravenous EVO301 in adults suffering from moderate to severe atopic dermatitis. Participants will receive either the active treatment or a placebo to determine the effectiveness of EVO301 in reducing symptoms associated with this chronic skin condition. The study aims to assess improvements in skin condition and overall quality of life for those affected by atopic dermatitis.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with chronic atopic dermatitis affecting at least 10% of their body surface area.
Not a fit: Patients experiencing significant flares of atopic dermatitis or those who have used biologic therapy recently may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could significantly improve the quality of life for patients with moderate to severe atopic dermatitis.
How similar studies have performed: Other studies have shown promise with similar biologic treatments for atopic dermatitis, indicating a potential for success with this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Males or non-pregnant, non-lactating females, age 18 years or older 2. Chronic atopic dermatitis for at least 6 months 3. BSA of AD involvement of at least 10% 4. EASI score of at least 16. Exclusion Criteria: 1. Significant AD flare with 4 weeks 2. Use of biologic therapy within 12 weeks 3. Regular use of tanning booth within 4 weeks 4. Skin condition that could interfere with study assessments
Where this trial is running
Coorparoo and 11 other locations
- Cornerstone Dermatology — Coorparoo, Australia (Recruiting)
- Momentum Clinical Research Darlinghurst — Darlinghurst, Australia (Recruiting)
- Pacific Clinical Research Network (PCRN) Auckland — Auckland, New Zealand (Recruiting)
- Optimal Clinical Trials North — Auckland, New Zealand (Recruiting)
- Optimal Clinical Trials — Auckland, New Zealand (Recruiting)
- Pacific Clinical Research Network (PCRN) Christchurch — Christchurch, New Zealand (Recruiting)
- Momentum Clinical Research Dunedin — Dunedin, New Zealand (Recruiting)
- Clinical Trials New Zealand Ltd — Hamilton, New Zealand (Recruiting)
- Momentum Clinical Research Lower Hutt — Hutt Central, New Zealand (Recruiting)
- Pacific Clinical Research Network (PCRN) Tasman — Nelson, New Zealand (Recruiting)
- Momentum Clinical Research Kapiti — Paraparaumu, New Zealand (Recruiting)
- Momentum Clinical Research Pukekohe — Pukekohe, New Zealand (Recruiting)
Study contacts
- Study coordinator: Polina Bukshpun
- Email: polina.bukshpun@evommune.com
- Phone: +1-818-536-2358
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.